• Register
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.


Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.


Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function.

Mutation of the VHL tumor suppressor is associated with the inherited von Hippel-Lindau (VHL) cancer syndrome and the majority of kidney cancers. VHL binds the ElonginC-ElonginB complex and regulates levels of hypoxia-inducible proteins. The structure of the ternary complex at 2.7 angstrom resolution shows two interfaces, one between VHL and ElonginC and another between ElonginC and ElonginB. Tumorigenic mutations frequently occur in a 35-residue domain of VHL responsible for ElonginC binding. A mutational patch on a separate domain of VHL indicates a second macromolecular binding site. The structure extends the similarities to the SCF (Skp1-Cul1-F-box protein) complex that targets proteins for degradation, supporting the hypothesis that VHL may function in an analogous pathway.

Pubmed ID: 10205047


  • Stebbins CE
  • Kaelin WG
  • Pavletich NP


Science (New York, N.Y.)

Publication Data

April 16, 1999

Associated Grants


Mesh Terms

  • Amino Acid Sequence
  • Binding Sites
  • Cell Cycle Proteins
  • Cloning, Molecular
  • Crystallography, X-Ray
  • Genes, Tumor Suppressor
  • Humans
  • Hydrogen Bonding
  • Ligases
  • Models, Molecular
  • Molecular Sequence Data
  • Mutation
  • Mutation, Missense
  • Neoplasms
  • Protein Conformation
  • Protein Folding
  • Protein Structure, Secondary
  • Proteins
  • S-Phase Kinase-Associated Proteins
  • Surface Properties
  • Transcription Factors
  • Tumor Suppressor Proteins
  • Ubiquitin-Protein Ligases
  • Von Hippel-Lindau Tumor Suppressor Protein
  • von Hippel-Lindau Disease